TLDR Some hormone-related drugs may protect brain cells in Parkinson's disease differently in men and women.
The document from August 1, 2016, explores the neuroprotective potential of estrogenic drugs and 5α-reductase inhibitors in Parkinson's disease (PD), with a focus on sex differences in PD incidence and progression. It reports that estrogen and compounds like raloxifene, progesterone, and dehydroepiandrosterone (DHEA) have shown neuroprotective effects in animal models, potentially mediated through estrogen receptors such as GPER1. The document also notes that 5α-reductase inhibitors like Dutasteride, which are used for benign prostatic hyperplasia and androgenic alopecia, have demonstrated neuroprotective effects in male mice. The findings suggest that these compounds could be optimized for personalized PD treatments based on sex, but more research is needed to fully understand their mechanisms and effectiveness. The research was supported by grants from the Canadian Institutes of Health Research and other scholarships.
Topical dutasteride is suggested as a low side-effect treatment for hair loss, with a proposed dose of 0.025% 1ml/day. It is considered better than finasteride due to its even inhibition of DHT isoforms and lower systemic absorption.
A 30-year-old man experienced significant hair regrowth and improved libido after using finasteride and dutasteride for androgeneticalopecia, with no adverse effects. He plans to reduce dutasteride dosage when trying to conceive and has been using topical minoxidil since 2015.
The conversation discusses the use of 5-alpha-reductaseinhibitors like finasteride and dutasteride for hair loss in transgender women, particularly in relation to testosterone suppression. The original poster has been using dutasteride and is considering stopping it due to undetectable testosterone levels.
Dutasteride 0.5 mg significantly reduces both scalp and hair follicle DHT, with a greater reduction in hair follicle DHT. The discussion questions which reduction is more important for androgeneticalopecia and diffuse thinning.
Dutasteride may inhibit androgen receptors in addition to reducing DHT, potentially explaining its effectiveness over finasteride for hair loss. Concerns about its impact on muscle growth are debated, with some suggesting no significant effects.
The conversation discusses that dutasteride may be more effective than finasteride for frontal hair loss due to higher 5ar Type 1 enzyme activity in that area. Some users question the validity of this information, while others confirm it with additional sources.
